Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Genentech Drug Patent Portfolio

Genentech owns 9 orange book drugs protected by 58 US patents with Nutropin Aq having the least patent protection, holding only 1 patent. And Rozlytrek with maximum patent protection, holding 14 patents. and owns 6 purple book drugs protected by 63 US patents with Herceptin having the least patent protection, holding only 1 patent. And Actemra with maximum patent protection, holding 35 patents. Given below is the list of Genentech's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12030959 Anti-IgE antibody therapy for multiple food allergies 20 Jul, 2043
Active
US11925648 Solid dosage form having excellent stability 21 Apr, 2041
Active
US12122789 Forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of making 15 Apr, 2041
Active
US12064438 Pharmaceutical preparation excellent in light stability and dissolution property 09 Oct, 2039
Active
US11534444 Treatment of SMA 04 Oct, 2038
Active
US12350273 01 Oct, 2038
Active
US11261198 Process for preparing substituted polycyclic pyridone derivative and crystal thereof 25 Sep, 2038
Active
US10398693 Pharmaceutical compositions and dosage forms 18 Jul, 2038
Active
US11253515 Pharmaceutical compositions and dosage forms 18 Jul, 2038
Active
US12410189 14 Jun, 2038
Active
US11028100 Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production 26 Apr, 2038
Active
US10759814 Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof 09 Aug, 2037
Active
US11306106 Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof 09 Aug, 2037
Active
US10738037 Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide 18 May, 2037
Active
US11091469 Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide 18 May, 2037
Active
US10590102 Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone 30 Dec, 2036
Active
US11254649 Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone 30 Dec, 2036
Active
US10478400 Immediate-release tablets containing combimetinib and methods of making and using the same 29 Dec, 2036
Active
US11938136 Compositions for treating spinal muscular atrophy 08 Nov, 2036
Active
US10851091 Benzoxazepin oxazolidinone compounds and methods of use 01 Jul, 2036
Active
US11760753 Benzoxazepin oxazolidinone compounds and methods of use 01 Jul, 2036
Active
US9650393 Benzoxazepin oxazolidinone compounds and methods of use 01 Jul, 2036
Active
US10590102 Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone 30 Jun, 2036
Active
US11254649 Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone 30 Jun, 2036
Active
US10478400 Immediate-release tablets containing combimetinib and methods of making and using the same 29 Jun, 2036
Active
US10392406 Substituted polycyclic pyridone derivatives and prodrugs thereof 27 Apr, 2036
Active
US10633397 Substituted polycyclic pyridone derivatives and prodrugs thereof 27 Apr, 2036
Active
US11827646 Compounds for treating spinal muscular atrophy 25 Jan, 2036
Active
US10112994 Methods of producing two chain proteins in bacteria 05 Nov, 2035
Active
US10336983 Method for increasing the specific production rate of eukaryotic cells 31 Jul, 2035
Active
US10208355 Method of treatment for glioblastoma by administering a VEGF antagonist 14 Jul, 2035
Active
US10274466 Elucidation of ion exchange chromatography input optimization 11 Jul, 2035
Active
US9969754 Compounds for treating spinal muscular atrophy 11 May, 2035
Active
US10561651 Methods for treating neuroblastoma 19 Feb, 2035
Active
US10231965 Molecules for administration to ROS1 mutant cancer cells 17 Feb, 2035
Active
US10017732 Cell culture compositions with antioxidants and methods for polypeptide production 25 Dec, 2034
Active
US11087354 Combination therapies 22 Dec, 2034
Active
US11087354 Combination therapies 22 Jun, 2034
Active
US9441035 Cell culture media and methods of antibody production 23 Apr, 2034
Active
US10676710 Cell culture compositions with antioxidants and methods for polypeptide production 14 Mar, 2034
Active
US10829732 Cell culture compositions with antioxidants and methods for polypeptide production 14 Mar, 2034
Active
US9765379 Harvest operations for recombinant proteins 10 Mar, 2034
Active
US10906934 Protein purification methods 12 Oct, 2033
Active
US10421984 Methods for reducing norleucine misincorporation into proteins using a microorganism comprising a mutant metA allele 19 Sep, 2033
Active
US9630988 Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration 13 Jun, 2033
Active
US9085565 Process for the preparation of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide 22 May, 2033
Active
US9649306 Treatment of diseases through administration of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide 22 May, 2033
Active
US10590164 Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration 19 Mar, 2033
Active
US9586955 Compounds for treating spinal muscular atrophy 08 Feb, 2033
Active
US10513697 CO2 profile cultivation 17 Sep, 2032
Active
US9750752 Subcutaneously administered anti-IL-6 receptor antibody 30 Aug, 2032
Active
US9539263 Subcutaneously administered anti-IL-6 receptor antibody for treatment of systemic sclerosis 23 May, 2032
Active
US8299057 Substituted indazole derivatives active as kinase inhibitors 10 Mar, 2032
Active
US10874677 Subcutaneously administered anti-IL-6 receptor antibody 02 Mar, 2032
Active
US9487809 Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase 14 Jan, 2032
Active
US10231981 Subcutaneously administered anti-IL-6 receptor antibody for treatment of juvenile idiopathic arthritis 03 Dec, 2031
Active
US11667720 Subcutaneously administered anti-IL-6 receptor antibody 07 Nov, 2031
Active
US8580264 Subcutaneously administered anti-IL-6 receptor antibody 07 Nov, 2031
Active
US8987441 Substituted polycyclic carbamoyl pyridone derivative prodrug 21 Sep, 2031
Active
US10704071 Decreasing lactate level and increasing polypeptide production by down regulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase 18 Aug, 2031
Active
US10662237 Method to improve virus filtration capacity 07 Aug, 2031
Active
US10011856 Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase 26 May, 2031
Active
US8927710 Substituted polycyclic carbamoylpyridone derivative 05 May, 2031
Active
US8512983 Production of proteins in glutamine-free cell culture media 04 Jan, 2031
Active
US10501769 Method for the production of a glycosylated immunoglobulin 25 Oct, 2030
Active
US11021728 Method for the production of a glycosylated immunoglobulin 25 Oct, 2030
Active
US11136610 Method for the production of a glycosylated immunoglobulin 25 Oct, 2030
Active
US11377678 Method for the production of a glycosylated immunoglobulin 25 Oct, 2030
Active
US8242104 Benzoxazepin P13K inhibitor compounds and methods of use 27 Sep, 2030
Active
US8343955 Benzoxazepin PI3K inhibitor compounds and methods of use 27 Sep, 2030
Active
US10982003 Production of proteins in glutamine-free cell culture media 06 Aug, 2030
Active
US9714293 Production of proteins in glutamine-free cell culture media 06 Aug, 2030
Active
US9815835 Substituted polycyclic carbamolypyridone derivative 14 Jun, 2030
Active
US7803839 Azetidines as MEK inhibitors for the treatment of proliferative diseases 10 May, 2030
Active
US7803839 Azetidines as MEK inhibitors for the treatment of proliferative diseases 10 Nov, 2029
Active
US8568720 High concentration antibody-containing liquid formulation 05 Nov, 2029
Active
US8460895 Method for producing recombinant proteins with a constant content of pCO2 in the medium 08 Aug, 2029
Active
US11136375 Method for production of antibody 19 Jul, 2029
Active
US11008394 High concentration antibody-containing liquid formulation 26 Dec, 2028
Active
US11359026 High concentration antibody-containing liquid formulation 26 Dec, 2028
Active
US11584798 High concentration antibody-containing liquid formulation 26 Dec, 2028
Active
US9278961 Pyridyl inhibitors of hedgehog signalling 15 Dec, 2028
Active
US7888364 Pyridyl inhibitors of hedgehog signalling 11 Nov, 2028
Active
US8673893 Substituted indazole derivatives active as kinase inhibitors 08 Jul, 2028
Active
US9029356 Substituted indazole derivatives active as kinase inhibitors 08 Jul, 2028
Active
US9085558 Substituted indazole derivatives active as kinase inhibitors 08 Jul, 2028
Active
US9255087 Substituted indazole derivatives active as kinase inhibitors 08 Jul, 2028
Active
US9616059 Substituted indazole derivatives active as kinase inhibitors 08 Jul, 2028
Active
US11078294 Prevention of disulfide bond reduction during recombinant production of polypeptides 08 Jul, 2028
Active
US8574869 Prevention of disulfide bond reduction during recombinant production of polypeptides 08 Jul, 2028
Active
US10906986 Prevention of disulfide bond reduction during recombinant production of polypeptides 08 Jul, 2028
Active
US10808037 Prevention of disulfide bond reduction during recombinant production of polypeptides 08 Jul, 2028
Active
US10759866 Prevention of disulfide bond reduction during recombinant production of polypeptides 08 Jul, 2028
Active
US11987637 Prevention of disulfide bond reduction during recombinant production of polypeptides 08 Jul, 2028
Active
US8398980 Subtypes of humanized antibody against interleukin-6 receptor 25 Feb, 2028
Active
US8362002 Azetidines as MEK inhibitors for the treatment of proliferative diseases 05 Apr, 2027
Active
US10450379 Method for treating joint damage 14 Nov, 2026
Active
US10654940 Method for treating joint damage 14 Nov, 2026
Active
US11597699 MEK inhibitors and methods of their use 05 Oct, 2026
Active
US8362002 Azetidines as MEK inhibitors for the treatment of proliferative diseases 05 Oct, 2026
Active
US8617550 Treatment of vasculitis with IL-6 antagonist 03 Mar, 2026
Active
US10034940 High concentration antibody and protein formulations 04 Nov, 2025
Active
US9790183 Pyridyl inhibitors of hedgehog signalling 02 Sep, 2025 Expired
US7976838 Therapy of autoimmune disease in a patient with an inadequate response to a TNF-α inhibitor 30 Jun, 2025
Active
US9902777 Methods for producing subtypes of humanized antibody against interleukin-6 receptor 28 May, 2025
Active
US8734800 Subtypes of humanized antibody against interleukin-6 receptor 24 Mar, 2025
Active
US7485704 Reducing protein A leaching during protein A affinity chromatography 08 Mar, 2025
Active
US8709409 Method for treating rheumatoid arthritis by administering an anti-IL-6 antibody and methotrexate 22 Jun, 2024
Active
US9795672 Treatment with anti-VEGF antibodies 28 May, 2024
Active
US10744201 Method for treating rheumatoid arthritis with a human IL-6 receptor antibody and methotrexate 28 Apr, 2024
Active
US7521052 Methods for treating interleukin-6 related diseases 28 Apr, 2024
Active
US8383773 Protein product and method for reducing biomass-biomass interactions 13 Dec, 2023
Active
US6921659 Protease-deficient cells 17 Oct, 2023
Active
US7332289 Method of purifying protein 04 Aug, 2023
Active
US9688775 System for antibody expression and assembly 31 Dec, 2022
Active
US6828121 Bacterial host strains 08 Jul, 2022
Active
US6716602 Metabolic rate shifts in fermentations expressing recombinant proteins 01 Nov, 2021
Active
US5763394 Human growth hormone aqueous formulation 09 Jun, 2015 Expired
US5654010 Composition for sustained release of human growth hormone 05 Aug, 2014 Expired
US5656297 Modulated release from biocompatible polymers 25 Jul, 2014 Expired
US6051259 Composition for sustained release of human growth hormone 02 Dec, 2012 Expired


Given below is the list of recent legal activities going on the following drug patents of Genentech.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 17 Jul, 2024 US8362002
Payment of Maintenance Fee, 12th Year, Large Entity 30 Apr, 2024 US8299057
Recordation of Patent eGrant 26 Mar, 2024 US11938136
Sequence Moved to Public Database 26 Mar, 2024 US11938136
Mail Patent eGrant Notification 26 Mar, 2024 US11938136
Patent Issue Date Used in PTA Calculation
Critical
26 Mar, 2024 US11938136
Email Notification
Critical
26 Mar, 2024 US11938136
Patent eGrant Notification 26 Mar, 2024 US11938136
Recordation of Patent Grant Mailed
Critical
26 Mar, 2024 US11938136
Mail Patent eGrant Notification 12 Mar, 2024 US11925648
Recordation of Patent eGrant 12 Mar, 2024 US11925648
Patent eGrant Notification 12 Mar, 2024 US11925648
Email Notification
Critical
12 Mar, 2024 US11925648
Patent Issue Date Used in PTA Calculation
Critical
12 Mar, 2024 US11925648
Recordation of Patent Grant Mailed
Critical
12 Mar, 2024 US11925648


Genentech Drug Patents' Oppositions Filed in EPO

Genentech drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 05, 2012, by Eip Limited. This opposition was filed on patent number EP06825554A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP13753131A Mar, 2020 Sandoz AG Opposition rejected
EP06825554A Jan, 2012 EIP Limited Opposition rejected


Genentech's Family Patents

Genentech drugs have patent protection in a total of 45 countries. It's US patent count contributes only to 16.5% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree.

Family Patents



Genentech Drug List

Given below is the complete list of Genentech's drugs and the patents protecting them.


1. Cotellic

Cotellic is protected by 13 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10590102
(Pediatric)
Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone 30 Dec, 2036
(10 years from now)
Active
US11254649
(Pediatric)
Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone 30 Dec, 2036
(10 years from now)
Active
US10478400
(Pediatric)
Immediate-release tablets containing combimetinib and methods of making and using the same 29 Dec, 2036
(10 years from now)
Active
US10590102 Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone 30 Jun, 2036
(10 years from now)
Active
US11254649 Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone 30 Jun, 2036
(10 years from now)
Active
US10478400 Immediate-release tablets containing combimetinib and methods of making and using the same 29 Jun, 2036
(10 years from now)
Active
US11087354
(Pediatric)
Combination therapies 22 Dec, 2034
(8 years from now)
Active
US11087354 Combination therapies 22 Jun, 2034
(8 years from now)
Active
US7803839
(Pediatric)
Azetidines as MEK inhibitors for the treatment of proliferative diseases 10 May, 2030
(4 years from now)
Active
US7803839 Azetidines as MEK inhibitors for the treatment of proliferative diseases 10 Nov, 2029
(3 years from now)
Active
US8362002
(Pediatric)
Azetidines as MEK inhibitors for the treatment of proliferative diseases 05 Apr, 2027
(1 year, 2 months from now)
Active
US11597699 MEK inhibitors and methods of their use 05 Oct, 2026
(8 months from now)
Active
US8362002 Azetidines as MEK inhibitors for the treatment of proliferative diseases 05 Oct, 2026
(8 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cotellic's drug page


2. Erivedge

Erivedge is protected by 3 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9278961 Pyridyl inhibitors of hedgehog signalling 15 Dec, 2028
(2 years from now)
Active
US7888364 Pyridyl inhibitors of hedgehog signalling 11 Nov, 2028
(2 years from now)
Active
US9790183 Pyridyl inhibitors of hedgehog signalling 02 Sep, 2025
(4 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Erivedge's drug page


3. Evrysdi

Evrysdi is protected by 7 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12122789 Forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of making 15 Apr, 2041
(15 years from now)
Active
US11534444 Treatment of SMA 04 Oct, 2038
(12 years from now)
Active
US12350273 01 Oct, 2038
(12 years from now)
Active
US11938136 Compositions for treating spinal muscular atrophy 08 Nov, 2036
(10 years from now)
Active
US11827646 Compounds for treating spinal muscular atrophy 25 Jan, 2036
(10 years from now)
Active
US9969754 Compounds for treating spinal muscular atrophy 11 May, 2035
(9 years from now)
Active
US9586955 Compounds for treating spinal muscular atrophy 08 Feb, 2033
(7 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Evrysdi's drug page


4. Itovebi

Itovebi is protected by 7 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12410189 14 Jun, 2038
(12 years from now)
Active
US11028100 Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production 26 Apr, 2038
(12 years from now)
Active
US10851091 Benzoxazepin oxazolidinone compounds and methods of use 01 Jul, 2036
(10 years from now)
Active
US11760753 Benzoxazepin oxazolidinone compounds and methods of use 01 Jul, 2036
(10 years from now)
Active
US9650393 Benzoxazepin oxazolidinone compounds and methods of use 01 Jul, 2036
(10 years from now)
Active
US8242104 Benzoxazepin P13K inhibitor compounds and methods of use 27 Sep, 2030
(4 years from now)
Active
US8343955 Benzoxazepin PI3K inhibitor compounds and methods of use 27 Sep, 2030
(4 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Itovebi's drug page


5. Nutropin Aq

Nutropin Aq is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5763394 Human growth hormone aqueous formulation 09 Jun, 2015
(10 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nutropin Aq's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Nutropin Aq Pen

Nutropin Aq Pen is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5763394 Human growth hormone aqueous formulation 09 Jun, 2015
(10 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nutropin Aq Pen's drug page


7. Nutropin Depot

Nutropin Depot is protected by 3 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5654010 Composition for sustained release of human growth hormone 05 Aug, 2014
(11 years ago)
Expired
US5656297 Modulated release from biocompatible polymers 25 Jul, 2014
(11 years ago)
Expired
US6051259 Composition for sustained release of human growth hormone 02 Dec, 2012
(13 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nutropin Depot's drug page


8. Rozlytrek

Rozlytrek is protected by 14 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10398693 Pharmaceutical compositions and dosage forms 18 Jul, 2038
(12 years from now)
Active
US11253515 Pharmaceutical compositions and dosage forms 18 Jul, 2038
(12 years from now)
Active
US10738037 Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide 18 May, 2037
(11 years from now)
Active
US11091469 Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide 18 May, 2037
(11 years from now)
Active
US10561651 Methods for treating neuroblastoma 19 Feb, 2035
(9 years from now)
Active
US10231965 Molecules for administration to ROS1 mutant cancer cells 17 Feb, 2035
(9 years from now)
Active
US9085565 Process for the preparation of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide 22 May, 2033
(7 years from now)
Active
US9649306 Treatment of diseases through administration of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide 22 May, 2033
(7 years from now)
Active
US8299057 Substituted indazole derivatives active as kinase inhibitors 10 Mar, 2032
(6 years from now)
Active
US8673893 Substituted indazole derivatives active as kinase inhibitors 08 Jul, 2028
(2 years from now)
Active
US9029356 Substituted indazole derivatives active as kinase inhibitors 08 Jul, 2028
(2 years from now)
Active
US9085558 Substituted indazole derivatives active as kinase inhibitors 08 Jul, 2028
(2 years from now)
Active
US9255087 Substituted indazole derivatives active as kinase inhibitors 08 Jul, 2028
(2 years from now)
Active
US9616059 Substituted indazole derivatives active as kinase inhibitors 08 Jul, 2028
(2 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rozlytrek's drug page


9. Xofluza

Xofluza is protected by 10 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11925648 Solid dosage form having excellent stability 21 Apr, 2041
(15 years from now)
Active
US12064438 Pharmaceutical preparation excellent in light stability and dissolution property 09 Oct, 2039
(13 years from now)
Active
US11261198 Process for preparing substituted polycyclic pyridone derivative and crystal thereof 25 Sep, 2038
(12 years from now)
Active
US10759814 Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof 09 Aug, 2037
(11 years from now)
Active
US11306106 Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof 09 Aug, 2037
(11 years from now)
Active
US10392406 Substituted polycyclic pyridone derivatives and prodrugs thereof 27 Apr, 2036
(10 years from now)
Active
US10633397 Substituted polycyclic pyridone derivatives and prodrugs thereof 27 Apr, 2036
(10 years from now)
Active
US8987441 Substituted polycyclic carbamoyl pyridone derivative prodrug 21 Sep, 2031
(5 years from now)
Active
US8927710 Substituted polycyclic carbamoylpyridone derivative 05 May, 2031
(5 years from now)
Active
US9815835 Substituted polycyclic carbamolypyridone derivative 14 Jun, 2030
(4 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xofluza's drug page


10. Actemra

Actemra is protected by 35 patents, out of which 6 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10336983 Method for increasing the specific production rate of eukaryotic cells 31 Jul, 2035
(9 years from now)
Active
US10017732 Cell culture compositions with antioxidants and methods for polypeptide production 25 Dec, 2034
(8 years from now)
Active
US10676710 Cell culture compositions with antioxidants and methods for polypeptide production 14 Mar, 2034
(8 years from now)
Active
US10829732 Cell culture compositions with antioxidants and methods for polypeptide production 14 Mar, 2034
(8 years from now)
Active
US9630988 Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration 13 Jun, 2033
(7 years from now)
Active
US10590164 Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration 19 Mar, 2033
(7 years from now)
Active
US9750752 Subcutaneously administered anti-IL-6 receptor antibody 30 Aug, 2032
(6 years from now)
Active
US9539263 Subcutaneously administered anti-IL-6 receptor antibody for treatment of systemic sclerosis 23 May, 2032
(6 years from now)
Active
US10874677 Subcutaneously administered anti-IL-6 receptor antibody 02 Mar, 2032
(6 years from now)
Active
US10231981 Subcutaneously administered anti-IL-6 receptor antibody for treatment of juvenile idiopathic arthritis 03 Dec, 2031
(5 years from now)
Active
US11667720 Subcutaneously administered anti-IL-6 receptor antibody 07 Nov, 2031
(5 years from now)
Active
US8580264 Subcutaneously administered anti-IL-6 receptor antibody 07 Nov, 2031
(5 years from now)
Active
US10662237 Method to improve virus filtration capacity 07 Aug, 2031
(5 years from now)
Active
US8512983 Production of proteins in glutamine-free cell culture media 04 Jan, 2031
(4 years from now)
Active
US10501769 Method for the production of a glycosylated immunoglobulin 25 Oct, 2030
(4 years from now)
Active
US11021728 Method for the production of a glycosylated immunoglobulin 25 Oct, 2030
(4 years from now)
Active
US11136610 Method for the production of a glycosylated immunoglobulin 25 Oct, 2030
(4 years from now)
Active
US11377678 Method for the production of a glycosylated immunoglobulin 25 Oct, 2030
(4 years from now)
Active
US10982003 Production of proteins in glutamine-free cell culture media 06 Aug, 2030
(4 years from now)
Active
US9714293 Production of proteins in glutamine-free cell culture media 06 Aug, 2030
(4 years from now)
Active
US8568720 High concentration antibody-containing liquid formulation 05 Nov, 2029
(3 years from now)
Active
US11136375 Method for production of antibody 19 Jul, 2029
(3 years from now)
Active
US11008394 High concentration antibody-containing liquid formulation 26 Dec, 2028
(2 years from now)
Active
US11359026 High concentration antibody-containing liquid formulation 26 Dec, 2028
(2 years from now)
Active
US11584798 High concentration antibody-containing liquid formulation 26 Dec, 2028
(2 years from now)
Active
US11078294 Prevention of disulfide bond reduction during recombinant production of polypeptides 08 Jul, 2028
(2 years from now)
Active
US8574869 Prevention of disulfide bond reduction during recombinant production of polypeptides 08 Jul, 2028
(2 years from now)
Active
US8398980 Subtypes of humanized antibody against interleukin-6 receptor 25 Feb, 2028
(2 years from now)
Active
US8617550 Treatment of vasculitis with IL-6 antagonist 03 Mar, 2026
(a month from now)
Active
US9902777 Methods for producing subtypes of humanized antibody against interleukin-6 receptor 28 May, 2025
(7 months ago)
Expired
US8734800 Subtypes of humanized antibody against interleukin-6 receptor 24 Mar, 2025
(9 months ago)
Expired
US8709409 Method for treating rheumatoid arthritis by administering an anti-IL-6 antibody and methotrexate 22 Jun, 2024
(1 year, 6 months ago)
Expired
US10744201 Method for treating rheumatoid arthritis with a human IL-6 receptor antibody and methotrexate 28 Apr, 2024
(1 year, 8 months ago)
Expired
US7521052 Methods for treating interleukin-6 related diseases 28 Apr, 2024
(1 year, 8 months ago)
Expired
US7332289 Method of purifying protein 04 Aug, 2023
(2 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Actemra's drug page


11. Avastin

Avastin is protected by 12 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10208355 Method of treatment for glioblastoma by administering a VEGF antagonist 14 Jul, 2035
(9 years from now)
Active
US10274466 Elucidation of ion exchange chromatography input optimization 11 Jul, 2035
(9 years from now)
Active
US9441035 Cell culture media and methods of antibody production 23 Apr, 2034
(8 years from now)
Active
US10906934 Protein purification methods 12 Oct, 2033
(7 years from now)
Active
US10513697 CO2 profile cultivation 17 Sep, 2032
(6 years from now)
Active
US9487809 Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase 14 Jan, 2032
(5 years from now)
Active
US10704071 Decreasing lactate level and increasing polypeptide production by down regulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase 18 Aug, 2031
(5 years from now)
Active
US10011856 Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase 26 May, 2031
(5 years from now)
Active
US8460895 Method for producing recombinant proteins with a constant content of pCO2 in the medium 08 Aug, 2029
(3 years from now)
Active
US10906986 Prevention of disulfide bond reduction during recombinant production of polypeptides 08 Jul, 2028
(2 years from now)
Active
US7485704 Reducing protein A leaching during protein A affinity chromatography 08 Mar, 2025
(10 months ago)
Expired
US9795672 Treatment with anti-VEGF antibodies 28 May, 2024
(1 year, 7 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Avastin's drug page


12. Herceptin

Herceptin is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10808037 Prevention of disulfide bond reduction during recombinant production of polypeptides 08 Jul, 2028
(2 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Herceptin's drug page


13. Lucentis

Lucentis is protected by 8 patents, out of which 5 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10112994 Methods of producing two chain proteins in bacteria 05 Nov, 2035
(9 years from now)
Active
US9765379 Harvest operations for recombinant proteins 10 Mar, 2034
(8 years from now)
Active
US10421984 Methods for reducing norleucine misincorporation into proteins using a microorganism comprising a mutant metA allele 19 Sep, 2033
(7 years from now)
Active
US8383773 Protein product and method for reducing biomass-biomass interactions 13 Dec, 2023
(2 years ago)
Expired
US6921659 Protease-deficient cells 17 Oct, 2023
(2 years ago)
Expired
US9688775 System for antibody expression and assembly 31 Dec, 2022
(3 years ago)
Expired
US6828121 Bacterial host strains 08 Jul, 2022
(3 years ago)
Expired
US6716602 Metabolic rate shifts in fermentations expressing recombinant proteins 01 Nov, 2021
(4 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lucentis's drug page


14. Rituxan

Rituxan is protected by 4 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10759866 Prevention of disulfide bond reduction during recombinant production of polypeptides 08 Jul, 2028
(2 years from now)
Active
US10450379 Method for treating joint damage 14 Nov, 2026
(9 months from now)
Active
US10654940 Method for treating joint damage 14 Nov, 2026
(9 months from now)
Active
US7976838 Therapy of autoimmune disease in a patient with an inadequate response to a TNF-α inhibitor 30 Jun, 2025
(6 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rituxan's drug page


15. Xolair

Xolair is protected by 3 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12030959 Anti-IgE antibody therapy for multiple food allergies 20 Jul, 2043
(17 years from now)
Active
US11987637 Prevention of disulfide bond reduction during recombinant production of polypeptides 08 Jul, 2028
(2 years from now)
Active
US10034940 High concentration antibody and protein formulations 04 Nov, 2025
(2 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xolair's drug page


Genentech News

Roche CEO calls on Switzerland to increase funding for new medications following agreement in the US - Bilyonaryo

22 Dec, 2025

Recursion's New CEO Discusses Transforming AI-Developed Medications into Clinical Evidence

01 Dec, 2025

Pharma 4.0: The Impact of AI on the Future of the Pharmaceutical Industry - TNGlobal

28 Oct, 2025

Biogen Directed to Compensate Genentech $88.3 Million for Previous Royalties Related to Cabilly Patents

09 Oct, 2025

See More